Core Insights - FG Nexus Inc. has been recognized as the top-performing SPAC sponsor by median returns and second by average returns according to a study by EarlyBirdCapital [1] Group 1: Company Leadership and Expertise - Under the leadership of Larry Swets and partners, FG Nexus has established a strong track record in the SPAC ecosystem, with nearly 20 years of experience [2] - The leadership team has collectively sponsored, served as officers, or advised 10 SPACs, successfully completing multiple business combinations while maintaining a disciplined approach [2][3] Group 2: SPAC Market Evolution and Strategy - The SPAC market has evolved significantly, and FG Nexus's experience across the lifecycle of these transactions provides a unique perspective [3] - The company's SPAC platform is integral to its broader investment strategy, focusing on growth-stage businesses in sectors like insurance and financial services [3] Group 3: Commitment to Quality and Long-term Value - FG Nexus emphasizes quality over quantity in SPAC sponsorship, aiming to bring operational capabilities and patient capital to high-quality businesses [4] - The company's approach prioritizes rigorous due diligence and operational transformation, aligning with its mission to build accountable public enterprises [4] Group 4: Future Plans and Digital Asset Strategy - FG Nexus is focused on building a digital asset treasury and a platform for tokenizing real-world assets, intending to enhance treasury yield through various strategies [5]

Core Viewpoint - Glass House Brands Inc. has appointed Alison Payne to its Board of Directors, effective January 27, 2026, to enhance its branding and marketing capabilities as it prepares for the rescheduling of cannabis [1][3]. Company Overview - Glass House Brands is recognized as one of the fastest-growing, vertically integrated cannabis companies in the U.S., focusing primarily on the California market [4]. - The company aims to build leading brands and offers a portfolio that includes Glass House Farms, PLUS Products, Allswell, and Mama Sue Wellness, along with a network of retail dispensaries [4]. Appointment Details - Alison Payne fills the vacant seat on the Board left by the passing of long-term member George Raveling in September 2025 [2]. - Payne has extensive international marketing experience, having held senior roles at Heineken, PepsiCo, Kellogg, and Diageo, and currently serves as the Chief Marketing Officer of Heineken, USA [3]. Strategic Importance - The appointment of Payne is seen as pivotal for Glass House as it prepares for potential growth and expansion opportunities, including geographic and product line diversification [3]. - Payne expressed her enthusiasm for joining the Board and contributing to the company's innovation and leadership in the cannabis market [4].

Core Insights - P10, Inc. and Bonaccord Capital Partners announced a collaboration with CAIS to enhance access to GP stakes solutions for financial advisors [1][2] - The partnership aims to broaden the reach of P10's middle-market expertise and support financial advisors in incorporating GP stakes into client portfolios [2][3] Company Overview - P10, Inc. is a leading private markets solutions provider with over $40 billion in assets under management as of September 30, 2025, focusing on Private Equity, Private Credit, and Venture Capital in access-constrained strategies [4][5] - Bonaccord Capital Partners specializes in providing growth capital and strategic support to mid-market private markets sponsors across various sectors, including private equity and real estate [5] Industry Trends - There is a significant increase in demand for alternative investments among financial advisors, with a recent survey indicating that 90% of advisors are currently allocating to alternatives and 88% plan to increase their allocations in the next two years [2][3] - Financial advisors are increasingly interested in GP stakes as a means to enhance diversification and gain exposure to established managers, which were historically dominated by institutional investors [3] CAIS Platform - CAIS serves over 2,000 wealth management firms and 62,000 financial advisors, overseeing approximately $7.5 trillion in end-client assets [7] - The platform is recognized for its innovation and leadership in the alternative investment space, providing a comprehensive operating system for financial advisors and alternative asset managers [8]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [3] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [3] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [3] - The company is also developing vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability [3] Upcoming Events - InflaRx will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, with a fireside chat scheduled for February 11 at 11:30 AM ET [1] - The company will conduct one-on-one investor meetings on February 11 during the same summit [1] - InflaRx will also present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25 at 8:40 AM ET [2] - One-on-one investor meetings will also be held on February 25 [2]

TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE: CLS) (TSX: CLS) (“Celestica” or the “Company”), a global leader in data center infrastructure and advanced technology solutions, today announced that the Annual Meeting of its Shareholders (the “Meeting”) will be held on Tuesday, May 19, 2026, at 9:30 a.m. EDT in a hybrid format to be specified in the Company’s upcoming definitive proxy statement related to the Meeting. Record Date Celestica also announced that it has set Friday, March 27, 202 ...

Core Viewpoint - Versamet Royalties Corporation has announced a bought deal offering of 9,100,000 common shares at a price of C$13.75 per share, aiming for gross proceeds of C$125 million, with an option for underwriters to purchase an additional 15% to cover over-allotments [1][2] Group 1: Offering Details - The offering is expected to close on or about February 9, 2026, pending necessary regulatory approvals [2] - The net proceeds from the offering and a concurrent private placement will be utilized to repay debt, fund future acquisitions, and for general corporate purposes [3] - The common shares will be offered via a prospectus supplement to the company's base shelf prospectus, available in all Canadian provinces except Quebec, and may also be offered in the U.S. under Rule 144A [4] Group 2: Company Overview - Versamet is an emerging mid-tier precious metals royalty and streaming company focused on creating long-term per share value for its shareholders through the acquisition of high-quality assets [6] - The company's common shares are traded on the Toronto Stock Exchange under the symbol "VMET" [6]

Group 1 - Digital Currency X Technology Inc. has regained compliance with Nasdaq's market value requirement after previously failing to maintain a minimum market value of listed securities of $35 million [1] - The company was notified on December 12, 2025, about its non-compliance, but the January Notice confirmed that it has met the requirement for the last 20 consecutive business days, from December 23, 2025, to January 22, 2026 [1] - The matter regarding compliance with Nasdaq Listing Rule 5550(b)(2) is now closed [1] Group 2 - Digital Currency X Technology Inc. is focused on developing infrastructure for secure cryptocurrency custody and storage solutions [2] - The company has treasury holdings exceeding $1.4 billion and is positioned at the forefront of institutional digital asset adoption [2] - The company's digital currency strategy includes treasury optimization, participation in decentralized finance (DeFi) ecosystems, and the development of advanced custody infrastructure [2]

Core Viewpoint - Springview Holdings Ltd has initiated its first pilot project for residential solar solutions in Singapore, marking a significant step in its sustainability strategy through collaboration with Jiangsu GSO New Energy Technology Co., Ltd [1][2]. Group 1: Pilot Project Details - The pilot project is located at 15 Jalan Nipah and aims to evaluate the economic, technical, and operational viability of rooftop solar solutions for landed residential properties in Singapore [2][3]. - A preliminary assessment indicates the potential for a solar photovoltaic system of up to approximately 60 kilowatts (kW), with an estimated daily generation of up to approximately 3.8 kilowatt-hours (kWh) per kW, leading to a potential total generation of approximately 228 kWh per day [3][10]. - The estimated monthly electricity savings from the solar generation could reach approximately S$2,000, translating to about S$24,000 annually, assuming substantial on-site self-consumption [4]. Group 2: Economic Viability - The indicative installation cost for the pilot project is approximately S$52,000, suggesting a potential simple payback period of about two to three years based on actual system performance and self-consumption levels [5]. - The project highlights the potential for rooftop solar solutions to provide significant long-term cost savings for homeowners with sustained electricity demand, in addition to environmental benefits [5]. Group 3: Collaboration and Future Plans - Under the collaboration framework, Springview will manage overall project delivery, regulatory coordination, and homeowner engagement, while GSO will provide technical expertise and engineering support [8]. - The pilot project aligns with the broader sustainability objectives of Singapore and may inform future offerings within Springview's residential design-and-build projects [7].

Core Viewpoint - Unicycive Therapeutics has received FDA acceptance for the resubmission of its New Drug Application for oxylanthanum carbonate (OLC), an investigational oral phosphate binder aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis, with a target action date set for June 27, 2026 [1][9]. Company Overview - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for kidney diseases, with its lead investigational treatment being oxylanthanum carbonate [8]. - The company also has a second investigational treatment, UNI-494, which is intended for conditions related to acute kidney injury and has received orphan drug designation from the FDA [8]. Product Details - OLC is designed to reduce the number and size of pills required for treating hyperphosphatemia, potentially improving patient adherence compared to existing treatments [4]. - The NDA for OLC is supported by data from three clinical studies and various preclinical studies, with no concerns raised by the FDA regarding the safety or efficacy data [2]. Financial Position - As of the end of 2025, the company reported an unaudited cash position of $41.3 million, which is expected to support its commercial launch activities and provide a cash runway into 2027 [3][9]. Regulatory Pathway - Unicycive is pursuing FDA approval for OLC through the 505(b)(2) regulatory pathway, backed by a strong global patent portfolio that includes exclusivity until 2031, with potential extensions until 2035 [5]. Market Context - Hyperphosphatemia is a critical condition affecting nearly all patients with End Stage Renal Disease, with over 450,000 individuals in the U.S. requiring medication annually to manage phosphate levels [6].

CHANDLER, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Building on decades of experience in serving embedded applications where low power, affordability and ease of development are critical, Microchip Technology (Nasdaq: MCHP) has added PIC32CM PL10 MCUs to its PIC32C family of Arm® Cortex®-M0+ core devices. PL10 MCUs feature a rich set of Core Independent Peripherals (CIPs), 5V operation, touch capabilities, integrated toolsets and safety compliance. The device family targets high-volume applications including ...